Logo
  • Home
  • AI Agent
  • Annotations
  • Files
  • Pricing and plans
  • BlogAboutContact us
    APIMCP
    Terms of servicePrivacy policy
  • Get the full experience

    We save the real magic for signed-in users.

ACH US​
HomeStock ScreenerDocument SearchChartingWatchlistsRecent Filings

Accendra Health Inc/va/(ACH US)

$0.14-0.0421.68%Ext:$0.17+0.0216.19%(Pre-Market · 13:15:29 UTC)
Ask AI
Doc SearchProfileEntity StructureFinancialsChartingShort InterestEmployees

Overview

ProfileEntity Structure

Documents

SEC Filings
Logo
  • Home
  • AI Agent
  • Annotations
  • Files
  • Pricing and plans
  • BlogAboutContact us
    APIMCP
    Terms of servicePrivacy policy
  • Get the full experience

    We save the real magic for signed-in users.

ACH US​
HomeStock ScreenerDocument SearchChartingWatchlistsRecent Filings

Accendra Health Inc/va/(ACH US)

$0.14-0.0421.68%Ext:$0.17+0.0216.19%(Pre-Market · 13:15:29 UTC)
Ask AI
Doc SearchProfileEntity StructureFinancialsChartingShort InterestEmployees

Overview

ProfileEntity Structure

Documents

SEC Filings

Financials & Metrics

FinancialsChartingShort InterestEmployees

Financials & Metrics

FinancialsChartingShort InterestEmployees

Accendra Health Inc/va/ — Company Profile

Accendra Health, Inc., along with its subsidiaries, operates globally as a comprehensive provider of healthcare solutions. The organization is structured into two primary operational divisions: Products & Healthcare Services and Patient Direct. The Products & Healthcare Services segment offers a wide array of goods and support services to both healthcare providers and manufacturers. Its extensive catalog includes medical and surgical supplies, featuring both established brands and its own proprietary merchandise. This segment also delivers crucial services to healthcare providers, such as supplier relationship management, advanced analytics, inventory optimization, and clinical supply oversight. Furthermore, it provides outsourced logistics and marketing assistance programs to its vendor partners. The Patient Direct segment is dedicated to delivering products and services for at-home patient care. Its offerings encompass critical therapeutic fields such as diabetes management, home-based respiratory support, and obstructive sleep apnea therapy. This division also supplies various other types of home medical equipment, as well as specialized patient care products for conditions like ostomy, wound management, urological needs, and incontinence. Accendra Health serves a diverse client base directly, including large multi-facility healthcare systems, independent hospitals, surgical facilities, and physicians' practices. Additionally, it reaches customers indirectly through third-party distribution channels. The enterprise was formerly known as Owens & Minor, Inc., adopting the name Accendra Health, Inc. in December 2025. Founded in 1882, its headquarters are located in Glen Allen, Virginia.

Sector
Health Care
Industry
Health Care Equipment & Supplies
Exchange
UN
CEO
Edward A. Pesicka
Headquarters
Glen Allen, VA, US
IPO Date
Mar 17, 1980
Employees
6,500
Website
www.accendrahealth.com

Key Metrics

Price
$0.51
Market Cap
$38.69M
Revenue (TTM)
$627.78M
Net Income (TTM)
$-6468000.00
EPS (TTM)
-0.08
P/E (TTM)
-0.04
P/B (TTM)
-0.08
Dividend Yield
2.27%
ROE (TTM)
1.39%
ROA (TTM)

Accendra Health Inc/va/ — Company Profile

Accendra Health, Inc., along with its subsidiaries, operates globally as a comprehensive provider of healthcare solutions. The organization is structured into two primary operational divisions: Products & Healthcare Services and Patient Direct. The Products & Healthcare Services segment offers a wide array of goods and support services to both healthcare providers and manufacturers. Its extensive catalog includes medical and surgical supplies, featuring both established brands and its own proprietary merchandise. This segment also delivers crucial services to healthcare providers, such as supplier relationship management, advanced analytics, inventory optimization, and clinical supply oversight. Furthermore, it provides outsourced logistics and marketing assistance programs to its vendor partners. The Patient Direct segment is dedicated to delivering products and services for at-home patient care. Its offerings encompass critical therapeutic fields such as diabetes management, home-based respiratory support, and obstructive sleep apnea therapy. This division also supplies various other types of home medical equipment, as well as specialized patient care products for conditions like ostomy, wound management, urological needs, and incontinence. Accendra Health serves a diverse client base directly, including large multi-facility healthcare systems, independent hospitals, surgical facilities, and physicians' practices. Additionally, it reaches customers indirectly through third-party distribution channels. The enterprise was formerly known as Owens & Minor, Inc., adopting the name Accendra Health, Inc. in December 2025. Founded in 1882, its headquarters are located in Glen Allen, Virginia.

Sector
Health Care
Industry
Health Care Equipment & Supplies
Exchange
UN
CEO
Edward A. Pesicka
Headquarters
Glen Allen, VA, US
IPO Date
Mar 17, 1980
Employees
6,500
Website
www.accendrahealth.com

Key Metrics

Price
$0.51
Market Cap
$38.69M
Revenue (TTM)
$627.78M
Net Income (TTM)
$-6468000.00
EPS (TTM)
-0.08
P/E (TTM)
-0.04
P/B (TTM)
-0.08
Dividend Yield
2.27%
ROE (TTM)
1.39%
ROA (TTM)
-0.27%
Operating Margin
-0.98%
Beta
1.12

Dividends

Last Dividend
$0.00
Last Yield
0.02%

Summary

Accendra Health, Inc., along with its subsidiaries, operates globally as a comprehensive provider of healthcare solutions. The organization is structured into two primary operational divisions: Products & Healthcare Services and Patient Direct. The Products & Healthcare Services segment offers a wide array of goods and support services to both healthcare providers and manufacturers. Its extensive catalog includes medical and surgical supplies, featuring both established brands and its own proprietary merchandise. This segment also delivers crucial services to healthcare providers, such as supplier relationship management, advanced analytics, inventory optimization, and clinical supply oversight. Furthermore, it provides outsourced logistics and marketing assistance programs to its vendor partners. The Patient Direct segment is dedicated to delivering products and services for at-home patient care. Its offerings encompass critical therapeutic fields such as diabetes management, home-based respiratory support, and obstructive sleep apnea therapy. This division also supplies various other types of home medical equipment, as well as specialized patient care products for conditions like ostomy, wound management, urological needs, and incontinence. Accendra Health serves a diverse client base directly, including large multi-facility healthcare systems, independent hospitals, surgical facilities, and physicians' practices. Additionally, it reaches customers indirectly through third-party distribution channels. The enterprise was formerly known as Owens & Minor, Inc., adopting the name Accendra Health, Inc. in December 2025. Founded in 1882, its headquarters are located in Glen Allen, Virginia.

Website
www.accendrahealth.com
Location
Glen Allen, VA, US
Phone804 723 7000
Employees6,500
CEOEdward A. Pesicka
Sector
Health Care
Industry
Health Care Equipment & Supplies
IPO DateMar 17, 1980

Ask AI

Company overview
Business model, segments, and competition.
Peer comparison
Metrics vs closest competitors.
Guidance & outlook
Forward guidance and assumptions.
Bull vs bear case
Upside drivers and key risks.
Valuation snapshot
Multiples vs history and peers.
Competitive moat
Defensibility and market position.
Management track record
Leadership and capital allocation history.
How it makes money
A short diagram of the business model.

Latest Documents

SEC Filings(3.1K)

Expand
  • 10-QQ3ended 30 Sept 20265 Nov
  • 8-KResults of Operations and Financial Condition5 Nov
  • Form 3Lloyd Scott MacRae4 Nov
  • 8-KDeparture of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers3 Nov
  • 8-KEntry into a Material Definitive Agreement2 Nov
  • 8-KNotice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing30 Oct
  • DEF 14ADefinitive proxy statement29 Oct
  • PRE 14APreliminary proxy statement19 Oct
  • 8-KNotice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing9 Oct
  • SC 13GACCENDRA HEALTH INC/VA/7 Oct
  • Form 4Gardner-Smith Kenneth6 Oct
  • 8-K/ADeparture of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers28 Sep
  • Form 4Leon Jonathan A24 Sep
  • 8-KDeparture of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers17 Sep
  • Form 144Coliseum Capital Management, LLC11 Sep
  • 8-KRegulation FD Disclosure17 Aug
  • 8-A12BRegistration of securities (Section 12(b))10 Aug
  • 8-KEntry into a Material Definitive Agreement10 Aug
  • 10-QQ2ended 30 Jun 202610 Aug
  • 8-KResults of Operations and Financial Condition10 Aug

News

  • Accendra Health, Inc. (ACH) Q3 2026 Earnings Call Transcript6 Nov
  • Accendra Health Reports Third Quarter 2026 Financial Results5 Nov
  • Accendra Health Announces Extension of $150 Million Receivables Sale Program To 20292 Nov
  • Accendra Health Receives Continued Listing Standard Notice from NYSE Regarding Market Capitalization and Stockholders' Equity; Intends to Submit Business Plan and Return to Compliance with NYSE Listing Standard​30 Oct
  • Accendra Health Receives Continued Listing Standard Notice from NYSE; Intends to Cure Deficiency and Return to Compliance with NYSE Listing Standard9 Oct
  • New Strong Sell Stocks for October 9th9 Oct
  • New Strong Sell Stocks for October 6th6 Oct
  • Accendra Health Names Kenneth Gardner-Smith as President and Chief Executive Officer to Lead the Company's Next Chapter of Growth17 Sep
  • Accendra Health Names Kenneth Gardner-Smith as President and Chief Executive Officer to Lead the Company's Next Chapter of Growth17 Sep
  • BlackRock Inc. Acquires New Stake in Accendra Health, Inc. $ACH4 Sep
  • Accendra Health Updates on Capital Allocation and CEO Succession Timing Plans17 Aug
  • Square Credit Card Levels Up: Rewards Built for Small Businesses and a New Way to Pay Vendors11 Aug

Mentions in Filings

  • #\*Acadia Healthcare Co., Inc. 281,754 3,786,774 \* Accendra Health, Inc. 430,261 950,877
    Dimensional ETF TrustAccendra Health Inc/va/·NPORT-EX - NT NPORT-P - Notification of late filing (portfolio holdings)·Q1 26·13 Aug
  • … that focus on operational efficiencies and offer pathways for career development. Competition The HME market is fragmented and highly competitive. AdaptHealth competes with other large national providers, including <strong>Accendra Health</strong>, Lincare Holdings Inc., Rotech Healthcare, Inc., Cardinal Health, Inc. and Quipt Home Medical Corp; regional providers, including DASCO Home Medical Equipment, Binson’s Medical Equipment, Inc., Norco, Inc., Protech …
    AdaptHealth Corp.Accendra Health Inc/va/·ARS - Annual report to security holders·FY25·28 Apr
  • … t and Logistics | 16,997 | 17,488 | | Genuine Parts | Distributors | 25,072 | 18,703 | | Henry Schein | Health Care Distributors | 13,602 | 10,008 | | Insight Enterprises | Technology Distributors | 8,580 | 4,608 | | <strong>Accendra Health</strong>1 | Health Care Distributors | 2,647 | 93 | | Performance Food Group | Food Distributors | 64,340 | 15,623 | | Pilgrim’s Pride | Packaged Foods and Meats | 18,436 | 7,472 | | SpartanNash2 | Food Distributors | 9,693 | …
    UNITED NATURAL FOODS INCAccendra Health Inc/va/·DEF 14A - Definitive proxy statement·Q2 27·4 Nov
  • … t and Logistics | 16,997 | 17,488 | | Genuine Parts | Distributors | 25,072 | 18,703 | | Henry Schein | Health Care Distributors | 13,602 | 10,008 | | Insight Enterprises | Technology Distributors | 8,580 | 4,608 | | <strong>Accendra Health</strong>1 | Health Care Distributors | 2,647 | 93 | | Performance Food Group | Food Distributors | 64,340 | 15,623 | | Pilgrim’s Pride | Packaged Foods and Meats | 18,436 | 7,472 | | SpartanNash2 | Food Distributors | 9,693 | …
    UNITED NATURAL FOODS INCAccendra Health Inc/va/·PRE 14A - Preliminary proxy statement·Q2 27·22 Oct
  • … 926.40 | | | | | 1261229 BC LTD 10% 04/15/32 14 | 335,000.00 | 342,035.00 | | | | | A&K TRAVEL G 7.5% 5/15/33 144A | 200,000.00 | 200,662.00 | | | | | ABU DHABI DEV 5.25% 10/54 144A | 100,000.00 | 89,000.00 | | | | | <strong>ACCENDRA HEALTH</strong> 9.75% 05/31/33 | 38,925.00 | 26,181.34 | | | | | ACRISURE LL 6.75% 7/01/32 144A | 50,000.00 | 45,817.00 | | | | | ACRISURE LLC 7.5% 11/6/30 144A | 125,000.00 | 121,892.50 | | | | | ACRISURE LLC 8.5% 06/29 144A | 200,0 …
    フィデリティ投信株式会社Accendra Health Inc/va/·Prospectus - Amended Securities Registration Statement·16 Oct·15 Oct
  • … 926.40 | | | | | 1261229 BC LTD 10% 04/15/32 14 | 335,000.00 | 342,035.00 | | | | | A&K TRAVEL G 7.5% 5/15/33 144A | 200,000.00 | 200,662.00 | | | | | ABU DHABI DEV 5.25% 10/54 144A | 100,000.00 | 89,000.00 | | | | | <strong>ACCENDRA HEALTH</strong> 9.75% 05/31/33 | 38,925.00 | 26,181.34 | | | | | ACRISURE LL 6.75% 7/01/32 144A | 50,000.00 | 45,817.00 | | | | | ACRISURE LLC 7.5% 11/6/30 144A | 125,000.00 | 121,892.50 | | | | | ACRISURE LLC 8.5% 06/29 144A | 200,0 …
    フィデリティ投信株式会社Accendra Health Inc/va/·Annual Report - Annual Securities Report (2026.01.21-2026.07.21)·16 Oct·15 Oct

Key Stats

Trading

Px/Chg 1D$0.51 / -9.43%
Prev Close$1.21
% of 52Wk H19.33%
Avg Volume840.43K
Beta1.12
Mkt Cap38.69M
FD Mkt Cap84.24M

Float

Shrs Out/Float76.58M / 56.19M
Short Float0.10%
Days to Cover6.69
Stock Repurchased$0.00

Current Valuation

EV1.87B
EV/EBITDA5.44
EV/Sales0.69
P/B-0.08
P/S0.01
FCF Yield56.66%
ROE1.39%
ROA-0.27%
Current Ratio0.49

Dividend

Cash$0.00
Yield2.27%
Yield (TTM)2.27%

Estimates

P/E-0.04
Est P/E0.00
Est EPS-0.06
Est PEG0.00

Valuation

Metric5Yr AvgMay '23May '24May '25May '26Oct '26
PRICE-BASED RATIOS
Price / Earnings-2.4945.09-44.97-1.64-4.87-6.03
Price / Sales0.160.100.180.060.390.06
Price / Book Value0.691.072.011.05-0.60-0.08
Price / Free Cash Flow1.476.373.49-8.934.661.78
ENTERPRISE VALUE METRICS
Enterprise Value2,907.73,733.14,020.02,685.92,226.41,872.8
Enterprise Value / Sales1.430.370.390.253.142.98
Enterprise Value / EBITDA26.4510.1310.2952.4425.7233.68
Enterprise Value / EBIT-30.2226.7138.96-12.58101.10-305.31

Financials

Full Financials
Millions USD5Yr CAGR (%)Dec '21Dec '22Dec '23Dec '24Dec '25
INCOME STATEMENT
Revenue-27.1%9,785.39,955.510,334.010,700.92,762.0
Gross Income-5.6%1,513.21,826.42,125.22,219.21,201.6
EBITDA-3.2%415.5368.4390.651.2364.7
EBIT-17.5%324.8139.8103.2-213.6150.2
Net Income—221.622.4-41.3-362.7-1,100.6
EPS (Diluted)—2.940.29-0.54-4.73-14.31
BALANCE SHEET
Cash & ST Inv50%55.769.5243.049.4282.0
Total Assets-8.8%3,536.65,386.35,093.34,656.22,451.8
Total Liabilities2.9%2,598.14,440.74,169.24,090.92,912.7
Total Shareholder Equity—938.5945.6924.2565.2-461.0
CASH FLOW
Net Operating Cash Flow—124.2325.0740.7161.5-101.8
Cap Ex41.9%-49.7-166.6-207.9-228.2-201.3
Free Cash Flow—74.5158.4532.8-66.7-303.1

Enterprise Value Bridge

Millions USD10 Nov '26
Price (As of 10 Nov '26)0.14
Basic Shares76.58
Market Cap11.0
Diluted Shares0.00
Fully Diluted Shares Outstanding0.00
Fully Diluted Market Cap-
+Consolidated Debt95.5
−In-the-Money Convertible Debt—
+Capital Leases-
+Operating Leases—
−Cash & Equivalents-26.6
−Short-term Investments-
+Total Preferred-
−In-the-Money Convertible Preferred—
−Investments in Unconsolidated Subs—
+Non-Controlling Interest-
+Pension Liabilities—
Enterprise Value79.9

Segment data

Revenue

by Products and services

  • Diabetes Product57%
  • Product And Service, Other21%
  • Wound Care14%
  • Urology8%

Revenue

by Geography

  • United States98%
  • Non-us2%

Related companies

Henry Schein Inc

HSIC US

Fuse Medical, Inc.

FZMD US

Neighpart International Corp.

NIDV US

WuXi AppTec Co., Ltd.

WUXAY US

Natera, Inc.

NTRA US

Labcorp Holdings Inc.

LH US

Guardant Health, Inc.

GH US

WuXi XDC Cayman Inc

2268 HK

Caris Life Sciences, Inc.

CAI US

Sonic Healthcare Ltd / ADR

SKHHY US

GRAIL, Inc.

GRAL US

Joinn Laboratories(China)Co.,Ltd.

603127 CG

-0.27%
Operating Margin
-0.98%
Beta
1.12

Dividends

Last Dividend
$0.00
Last Yield
0.02%

Summary

Accendra Health, Inc., along with its subsidiaries, operates globally as a comprehensive provider of healthcare solutions. The organization is structured into two primary operational divisions: Products & Healthcare Services and Patient Direct. The Products & Healthcare Services segment offers a wide array of goods and support services to both healthcare providers and manufacturers. Its extensive catalog includes medical and surgical supplies, featuring both established brands and its own proprietary merchandise. This segment also delivers crucial services to healthcare providers, such as supplier relationship management, advanced analytics, inventory optimization, and clinical supply oversight. Furthermore, it provides outsourced logistics and marketing assistance programs to its vendor partners. The Patient Direct segment is dedicated to delivering products and services for at-home patient care. Its offerings encompass critical therapeutic fields such as diabetes management, home-based respiratory support, and obstructive sleep apnea therapy. This division also supplies various other types of home medical equipment, as well as specialized patient care products for conditions like ostomy, wound management, urological needs, and incontinence. Accendra Health serves a diverse client base directly, including large multi-facility healthcare systems, independent hospitals, surgical facilities, and physicians' practices. Additionally, it reaches customers indirectly through third-party distribution channels. The enterprise was formerly known as Owens & Minor, Inc., adopting the name Accendra Health, Inc. in December 2025. Founded in 1882, its headquarters are located in Glen Allen, Virginia.

Website
www.accendrahealth.com
Location
Glen Allen, VA, US
Phone804 723 7000
Employees6,500
CEOEdward A. Pesicka
Sector
Health Care
Industry
Health Care Equipment & Supplies
IPO DateMar 17, 1980

Ask AI

Company overview
Business model, segments, and competition.
Peer comparison
Metrics vs closest competitors.
Guidance & outlook
Forward guidance and assumptions.
Bull vs bear case
Upside drivers and key risks.
Valuation snapshot
Multiples vs history and peers.
Competitive moat
Defensibility and market position.
Management track record
Leadership and capital allocation history.
How it makes money
A short diagram of the business model.

Latest Documents

SEC Filings(3.1K)

Expand
  • 10-QQ3ended 30 Sept 20265 Nov
  • 8-KResults of Operations and Financial Condition5 Nov
  • Form 3Lloyd Scott MacRae4 Nov
  • 8-KDeparture of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers3 Nov
  • 8-KEntry into a Material Definitive Agreement2 Nov
  • 8-KNotice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing30 Oct
  • DEF 14ADefinitive proxy statement29 Oct
  • PRE 14APreliminary proxy statement19 Oct
  • 8-KNotice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing9 Oct
  • SC 13GACCENDRA HEALTH INC/VA/7 Oct
  • Form 4Gardner-Smith Kenneth6 Oct
  • 8-K/ADeparture of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers28 Sep
  • Form 4Leon Jonathan A24 Sep
  • 8-KDeparture of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers17 Sep
  • Form 144Coliseum Capital Management, LLC11 Sep
  • 8-KRegulation FD Disclosure17 Aug
  • 8-A12BRegistration of securities (Section 12(b))10 Aug
  • 8-KEntry into a Material Definitive Agreement10 Aug
  • 10-QQ2ended 30 Jun 202610 Aug
  • 8-KResults of Operations and Financial Condition10 Aug

News

  • Accendra Health, Inc. (ACH) Q3 2026 Earnings Call Transcript6 Nov
  • Accendra Health Reports Third Quarter 2026 Financial Results5 Nov
  • Accendra Health Announces Extension of $150 Million Receivables Sale Program To 20292 Nov
  • Accendra Health Receives Continued Listing Standard Notice from NYSE Regarding Market Capitalization and Stockholders' Equity; Intends to Submit Business Plan and Return to Compliance with NYSE Listing Standard​30 Oct
  • Accendra Health Receives Continued Listing Standard Notice from NYSE; Intends to Cure Deficiency and Return to Compliance with NYSE Listing Standard9 Oct
  • New Strong Sell Stocks for October 9th9 Oct
  • New Strong Sell Stocks for October 6th6 Oct
  • Accendra Health Names Kenneth Gardner-Smith as President and Chief Executive Officer to Lead the Company's Next Chapter of Growth17 Sep
  • Accendra Health Names Kenneth Gardner-Smith as President and Chief Executive Officer to Lead the Company's Next Chapter of Growth17 Sep
  • BlackRock Inc. Acquires New Stake in Accendra Health, Inc. $ACH4 Sep
  • Accendra Health Updates on Capital Allocation and CEO Succession Timing Plans17 Aug
  • Square Credit Card Levels Up: Rewards Built for Small Businesses and a New Way to Pay Vendors11 Aug

Mentions in Filings

  • #\*Acadia Healthcare Co., Inc. 281,754 3,786,774 \* Accendra Health, Inc. 430,261 950,877
    Dimensional ETF TrustAccendra Health Inc/va/·NPORT-EX - NT NPORT-P - Notification of late filing (portfolio holdings)·Q1 26·13 Aug
  • … that focus on operational efficiencies and offer pathways for career development. Competition The HME market is fragmented and highly competitive. AdaptHealth competes with other large national providers, including <strong>Accendra Health</strong>, Lincare Holdings Inc., Rotech Healthcare, Inc., Cardinal Health, Inc. and Quipt Home Medical Corp; regional providers, including DASCO Home Medical Equipment, Binson’s Medical Equipment, Inc., Norco, Inc., Protech …
    AdaptHealth Corp.Accendra Health Inc/va/·ARS - Annual report to security holders·FY25·28 Apr
  • … t and Logistics | 16,997 | 17,488 | | Genuine Parts | Distributors | 25,072 | 18,703 | | Henry Schein | Health Care Distributors | 13,602 | 10,008 | | Insight Enterprises | Technology Distributors | 8,580 | 4,608 | | <strong>Accendra Health</strong>1 | Health Care Distributors | 2,647 | 93 | | Performance Food Group | Food Distributors | 64,340 | 15,623 | | Pilgrim’s Pride | Packaged Foods and Meats | 18,436 | 7,472 | | SpartanNash2 | Food Distributors | 9,693 | …
    UNITED NATURAL FOODS INCAccendra Health Inc/va/·DEF 14A - Definitive proxy statement·Q2 27·4 Nov
  • … t and Logistics | 16,997 | 17,488 | | Genuine Parts | Distributors | 25,072 | 18,703 | | Henry Schein | Health Care Distributors | 13,602 | 10,008 | | Insight Enterprises | Technology Distributors | 8,580 | 4,608 | | <strong>Accendra Health</strong>1 | Health Care Distributors | 2,647 | 93 | | Performance Food Group | Food Distributors | 64,340 | 15,623 | | Pilgrim’s Pride | Packaged Foods and Meats | 18,436 | 7,472 | | SpartanNash2 | Food Distributors | 9,693 | …
    UNITED NATURAL FOODS INCAccendra Health Inc/va/·PRE 14A - Preliminary proxy statement·Q2 27·22 Oct
  • … 926.40 | | | | | 1261229 BC LTD 10% 04/15/32 14 | 335,000.00 | 342,035.00 | | | | | A&K TRAVEL G 7.5% 5/15/33 144A | 200,000.00 | 200,662.00 | | | | | ABU DHABI DEV 5.25% 10/54 144A | 100,000.00 | 89,000.00 | | | | | <strong>ACCENDRA HEALTH</strong> 9.75% 05/31/33 | 38,925.00 | 26,181.34 | | | | | ACRISURE LL 6.75% 7/01/32 144A | 50,000.00 | 45,817.00 | | | | | ACRISURE LLC 7.5% 11/6/30 144A | 125,000.00 | 121,892.50 | | | | | ACRISURE LLC 8.5% 06/29 144A | 200,0 …
    フィデリティ投信株式会社Accendra Health Inc/va/·Prospectus - Amended Securities Registration Statement·16 Oct·15 Oct
  • … 926.40 | | | | | 1261229 BC LTD 10% 04/15/32 14 | 335,000.00 | 342,035.00 | | | | | A&K TRAVEL G 7.5% 5/15/33 144A | 200,000.00 | 200,662.00 | | | | | ABU DHABI DEV 5.25% 10/54 144A | 100,000.00 | 89,000.00 | | | | | <strong>ACCENDRA HEALTH</strong> 9.75% 05/31/33 | 38,925.00 | 26,181.34 | | | | | ACRISURE LL 6.75% 7/01/32 144A | 50,000.00 | 45,817.00 | | | | | ACRISURE LLC 7.5% 11/6/30 144A | 125,000.00 | 121,892.50 | | | | | ACRISURE LLC 8.5% 06/29 144A | 200,0 …
    フィデリティ投信株式会社Accendra Health Inc/va/·Annual Report - Annual Securities Report (2026.01.21-2026.07.21)·16 Oct·15 Oct

Key Stats

Trading

Px/Chg 1D$0.51 / -9.43%
Prev Close$1.21
% of 52Wk H19.33%
Avg Volume840.43K
Beta1.12
Mkt Cap38.69M
FD Mkt Cap84.24M

Float

Shrs Out/Float76.58M / 56.19M
Short Float0.10%
Days to Cover6.69
Stock Repurchased$0.00

Current Valuation

EV1.87B
EV/EBITDA5.44
EV/Sales0.69
P/B-0.08
P/S0.01
FCF Yield56.66%
ROE1.39%
ROA-0.27%
Current Ratio0.49

Dividend

Cash$0.00
Yield2.27%
Yield (TTM)2.27%

Estimates

P/E-0.04
Est P/E0.00
Est EPS-0.06
Est PEG0.00

Valuation

Metric5Yr AvgMay '23May '24May '25May '26Oct '26
PRICE-BASED RATIOS
Price / Earnings-2.4945.09-44.97-1.64-4.87-6.03
Price / Sales0.160.100.180.060.390.06
Price / Book Value0.691.072.011.05-0.60-0.08
Price / Free Cash Flow1.476.373.49-8.934.661.78
ENTERPRISE VALUE METRICS
Enterprise Value2,907.73,733.14,020.02,685.92,226.41,872.8
Enterprise Value / Sales1.430.370.390.253.142.98
Enterprise Value / EBITDA26.4510.1310.2952.4425.7233.68
Enterprise Value / EBIT-30.2226.7138.96-12.58101.10-305.31

Financials

Full Financials
Millions USD5Yr CAGR (%)Dec '21Dec '22Dec '23Dec '24Dec '25
INCOME STATEMENT
Revenue-27.1%9,785.39,955.510,334.010,700.92,762.0
Gross Income-5.6%1,513.21,826.42,125.22,219.21,201.6
EBITDA-3.2%415.5368.4390.651.2364.7
EBIT-17.5%324.8139.8103.2-213.6150.2
Net Income—221.622.4-41.3-362.7-1,100.6
EPS (Diluted)—2.940.29-0.54-4.73-14.31
BALANCE SHEET
Cash & ST Inv50%55.769.5243.049.4282.0
Total Assets-8.8%3,536.65,386.35,093.34,656.22,451.8
Total Liabilities2.9%2,598.14,440.74,169.24,090.92,912.7
Total Shareholder Equity—938.5945.6924.2565.2-461.0
CASH FLOW
Net Operating Cash Flow—124.2325.0740.7161.5-101.8
Cap Ex41.9%-49.7-166.6-207.9-228.2-201.3
Free Cash Flow—74.5158.4532.8-66.7-303.1

Enterprise Value Bridge

Millions USD10 Nov '26
Price (As of 10 Nov '26)0.14
Basic Shares76.58
Market Cap11.0
Diluted Shares0.00
Fully Diluted Shares Outstanding0.00
Fully Diluted Market Cap-
+Consolidated Debt95.5
−In-the-Money Convertible Debt—
+Capital Leases-
+Operating Leases—
−Cash & Equivalents-26.6
−Short-term Investments-
+Total Preferred-
−In-the-Money Convertible Preferred—
−Investments in Unconsolidated Subs—
+Non-Controlling Interest-
+Pension Liabilities—
Enterprise Value79.9

Segment data

Revenue

by Products and services

  • Diabetes Product57%
  • Product And Service, Other21%
  • Wound Care14%
  • Urology8%

Revenue

by Geography

  • United States98%
  • Non-us2%

Related companies

Henry Schein Inc

HSIC US

Fuse Medical, Inc.

FZMD US

Neighpart International Corp.

NIDV US

WuXi AppTec Co., Ltd.

WUXAY US

Natera, Inc.

NTRA US

Labcorp Holdings Inc.

LH US

Guardant Health, Inc.

GH US

WuXi XDC Cayman Inc

2268 HK

Caris Life Sciences, Inc.

CAI US

Sonic Healthcare Ltd / ADR

SKHHY US

GRAIL, Inc.

GRAL US

Joinn Laboratories(China)Co.,Ltd.

603127 CG